Harry Visit 2: 68-year-old male with progressive dementia returns for follow-up visit
| Title: | Harry Visit 2: 68-year-old male with progressive dementia returns for follow-up visit |
| Topic: | Geriatrics |
| Relevant Terms: | Alzheimer’s Disease |
| Primary Audience: | Primary care practitioners |
| Launch Date: | 22-Feb-10 |
| Credits: | 0.5 AMA PRA Category 1 Credit™ |
| Expiration Date: | The accreditation for this activity has expired. |
| Curriculum Name: | Meet and Treat Harry |
Learning Objectives
Upon completion of the activity, participants should be able to:
- Identify the continuum and progressive disease burden associated with Alzheimer's disease (AD).
- Identify 2 clinical characteristics that can differentiate between early stage Alzheimer's disease and other dementia syndromes.
- Explain methods of neuroimaging that can aid in the evaluation of patients with dementia.
- Define one potential benefit of implementing timely initiation of AD pharmacotherapy.
Faculty
COURSE VIEWING REQUIREMENTS
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 0.5 hour
| PC
Internet Explorer (v6 or greater), or Firefox
|
MAC Safari |
ESTIMATED TIME TO COMPLETE THIS ACTIVITY: 0.5 hour
SPONSOR
This activity is sponsored by Albert Einstein College of Medicine in collaboration with SciMed and RealCME.

INTENDED AUDIENCE: Primary care physicians and other health care professionals involved in the management of patients with Alzheimer's Disease.
STATEMENT OF NEED
Poor identification and recognition of AD can have profound consequences for both the patient and their caregiver. A delay in diagnosis postpones patient care and treatment allowing for disease progression, putting the patient at risk, and increasing caregiver burden:
- Primary care physicians (PCP) are insufficiently educated on geriatric neurological disorders (eg Alzheimer's disease) and as such inherently fail to appreciate the burden of AD, leading to the mistaken belief that there is little value in the diagnosis of AD. This ultimately results in a significant delay in diagnosis and treatment, diminished patient quality of life, and increased risk of caregiver burden, health crisis, and institutionalization.
- Furthermore, PCPs may inadequately identify early signs of AD from other types of dementia syndromes, as they may be unaware of distinguishing clinical characteristics and innovative neuroimaging tools. This may lead to misdiagnosis, suboptimal patient care, and potentially incorrect treatment plans.
- In addition, PCPs may be inadequately educated on the most recent AD clinical trial results, and may lack the knowledge and confidence in applying these findings to their patients with AD. Therefore, early-stage AD patients may not receive the highest standard of care, putting them at risk for health crises including falls, use of physical or chemical restraints, and institutionalization.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Albert Einstein College of Medicine and SciMed. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Albert Einstein College of Medicine designates this educational activity for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
DISCLOSURE STATEMENT
Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
Albert Einstein College of Medicine CCME Staff, and the staff of RealCME have no conflicts of interest with commercial interest related directly or indirectly to this educational activity. Shari Fallet, D.O., employed by SciMed and a member of the planning committee, has disclosed that she owns stock with Pfizer.
FACULTY DISCLOSURES
Charles Cefalu, MD: No financial disclosures.
George T. Grossberg, MD: Bristol-Myers Squibb Company, Elan, Novartis, Pfizer Inc (Grants/Research); Accera, Forest Laboratories, Novartis, Pfizer Inc (Consultant).
Gary Kennedy, MD: Forest Laboratories (Grants/Research); Wyeth (Speaker's Bureau).
Murray A. Raskind, MD: Forest Laboratories (Speaker's Bureau).
George T. Grossberg, MD: Bristol-Myers Squibb Company, Elan, Novartis, Pfizer Inc (Grants/Research); Accera, Forest Laboratories, Novartis, Pfizer Inc (Consultant).
Gary Kennedy, MD: Forest Laboratories (Grants/Research); Wyeth (Speaker's Bureau).
Murray A. Raskind, MD: Forest Laboratories (Speaker's Bureau).
OFF-LABEL PRODUCT DISCUSSION
Faculty have indicated that this activity does not include off-label information.
METHOD OF PARTICIPATION AND RECEIVING CME/CE CREDIT
There are no fees for participating in and receiving credit for this activity. The participant must read the objectives and enduring material and must answer the multiple-choice online post-test. Please complete the evaluation form, which provides each participant with the opportunity to comment on the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias, and his/her views on future educational needs. A score of at least 70% is required to successfully complete this activity. The participant may take the test until successfully passed. Credit is available through February, 2011.
DISCLAIMER
The opinions and recommendations expressed by faculty in this activity are their own and do not necessarily represent the views of Albert Einstein College of Medicine, Montefiore Medical Center, and SciMed. Please review complete prescribing information for specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects, before administering pharmacologic therapy to patients.
COPYRIGHT INFORMATION
Copyright © 2010 Albert Einstein College of Medicine. All rights reserved. No part of this material may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations.
PRIVACY POLICY
Albert Einstein College of Medicine, Center for Continuing Medical Education (Einstein) protects the privacy of personal and other information regarding participants and educational collaborators. Einstein will not release personally identifiable information to a third party without the individual's consent, except such information as is required for reporting purposes to the ACCME.
Einstein maintains physical, electronic, and procedural safeguards that comply with federal regulations to protect against the loss, misuse or alteration of information that we have collected from you.
Additional information regarding Albert Einstein College of Medicine's Privacy Policy can be viewed at http://www.mecme.org/site/privacy.php.
If you have questions about this CME activity, please contact Albert Einstein College of Medicine at 1-718-920-6674 or cme@montefiore.org.
RELEASE DATE: February 22, 2010
TERMINATION DATE: February 21, 2011
TERMINATION DATE: February 21, 2011
ACKNOWLEDGEMENT
This activity is supported by an educational grant from Pfizer.



